Drug Trial Radar · NCT06368921
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 19, 2024
Primary completion
Sep 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors.
Conditions
- Solid Tumor
Interventions
VRT106Biological
intratumoral injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of escalating doses of intratumoral injection of VRT106.Time frame: About 2 years
- Characterize the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) levels.Time frame: About 2 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Affiliated Cancer Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.